John M. Reher

John M. Reher created the Brain Trust Accelerator Fund in 2006. The goal of this venture capital fund is to earn an attractive rate of return by creating and investing in early-stage medical companies that address brain-related diseases. The general partner of the fund donates a portion of its management fee and the carried interest to brain disease charities, which provide deal flow and advisory services. Current investments include Amnestix (sold to Sygnis Pharma), Neurofluidics and Satoris.

He was founding president and executive director of Accelerate Brain Cancer Cure, Inc. (ABC2) from 2001-2006. ABC2 is a non-profit organization dedicated to accelerating therapies for treatment of brain cancer by employing venture principles to this philanthropic endeavor.

Mr. Reher previously had over 12 years of venture capital experience as a general partner and co-founder of Medicus Venture Partners, an early-stage healthcare venture partnership with investments including Biosite Diagnostics, Inhale Therapeutic Systems (now Nektar), Tularik, and other successful companies.

Before entering the venture industry in 1989, Mr. Reher held financial, marketing, licensing, acquisitions and overall team leader positions for Genentech (1982-1989) and G.D. Searle Pharmaceuticals (1974-1981).

Mr. Reher has taught college courses in Economics, Finance and Investments. He received a Masters of Management degree from Northwestern University and a B.S. in Mathematics and Business Economics from Illinois Benedictine University.